CD276 and colon adenocarcinoma: <h4>Background</h4>Colon adenocarcinoma (COAD), although the third-most common type of gastrointestinal tumors, still lacks specific biomarkers for early diagnosis, treatment, and prognosis.<h4>Aims</h4>This study aimed to evaluate the CD276 in tumorigenesis, prognosis and immunity for colon adenocarcinoma.<h4>Methods and results</h4>The CD276 expression in colon adenocarcinoma was established by using RNA-sequencing transcriptomic data of The Cancer Genome Atlas (TCGA) databases.